Article

Additional Outcomes and Subgroup Analyses of NXY-059 for Acute Ischemic Stroke in the SAINT I Trial

Acute Stroke Unit & Cerebrovascular Clinic, University Department of Medicine & Therapeutics, Gardiner Institute, Western Infirmary, 44 Church St, Glasgow, Scotland G11 6NT.
Stroke (Impact Factor: 6.02). 01/2007; 37(12):2970-8. DOI: 10.1161/01.STR.0000249410.91473.44
Source: PubMed

ABSTRACT NXY-059 is a free radical-trapping neuroprotectant demonstrated to reduce disability from ischemic stroke. We conducted analyses on additional end points and sensitivity analyses to confirm our findings.
We randomized 1722 patients with acute ischemic stroke to a 72-hour infusion of placebo or intravenous NXY-059 within 6 hours of stroke onset. The primary outcome was disability at 90 days, as measured by the modified Rankin Scale (mRS), a 6-point scale ranging from 0 (no residual symptoms) to 5 (bed-bound, requiring constant care). Additional and exploratory analyses included mRS at 7 and 30 days; subgroup interactions with final mRS; assessments of activities of daily living by Barthel index; and National Institutes of Health Stroke Scale (NIHSS) neurological scores at 7 and 90 days.
NXY-059 significantly improved the distribution of the mRS disability score compared with placebo at 7, 30, and 90 days (Cochran-Mantel-Haenszel test P=0.002, 0.004, 0.038, respectively; 90-day common odds ratio 1.20; 95% CI, 1.01 to 1.42). The benefit was not attributable to any specific baseline characteristic, stratification variable or subgroup interaction. Neurological scores were improved at 7 days (odds ratio [OR], 1.46; 95% CI, 1.13, 1.89; P=0.003) and the Barthel index was improved at 7 and 30 days (OR, 1.55; 95% CI, 1.22, 1.98; P<0.0001; OR, 1.27; 95% CI, 1.01, 1.59; P=0.02).
NXY-059 within 6 hours of acute ischemic stroke significantly reduced disability. Benefit on neurological scores and activities of daily living was detectable early but not significant at 90 days; however, our trial was underpowered to measure effects on the neurological examination. The benefit on disability is not confounded by interactions and is supported by other outcome measures.

0 Followers
 · 
100 Views
 · 
0 Downloads
  • Source
    • "), CPI-1189 (Centaur [433] [434]), disufenton sodium (Cerovive, NXY-059, AstraZeneca, which was in Phase III clinical trials for the treatment of acute ischemic stroke [435] [436] [437] [438] [439] [440] [441] [442] [443] [444] [445]), FR-210575 (Fujisawa [446]), MDL-101002 (Hoechst Marion Roussel, now sanofi [447, 448]), and raxofelast (IRFI-016, Biomedica Foscama Industria [449–452]). "
  • Source
    • "), CPI-1189 (Centaur [433] [434]), disufenton sodium (Cerovive, NXY-059, AstraZeneca, which was in Phase III clinical trials for the treatment of acute ischemic stroke [435] [436] [437] [438] [439] [440] [441] [442] [443] [444] [445]), FR-210575 (Fujisawa [446]), MDL-101002 (Hoechst Marion Roussel, now sanofi [447, 448]), and raxofelast (IRFI-016, Biomedica Foscama Industria [449–452]). "
  • Source
    • "), CPI-1189 (Centaur [433] [434]), disufenton sodium (Cerovive, NXY-059, AstraZeneca, which was in Phase III clinical trials for the treatment of acute ischemic stroke [435] [436] [437] [438] [439] [440] [441] [442] [443] [444] [445]), FR-210575 (Fujisawa [446]), MDL-101002 (Hoechst Marion Roussel, now sanofi [447, 448]), and raxofelast (IRFI-016, Biomedica Foscama Industria [449–452]). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cognitive enhancers (nootropics) are drugs to treat cognition deficits in patients suffering from Alzheimer's disease, schizophrenia, stroke, attention deficit hyperactivity disorder, or aging. Cognition refers to a capacity for information processing, applying knowledge, and changing preferences. It involves memory, attention, executive functions, perception, language, and psychomotor functions. The term nootropics was coined in 1972 when memory enhancing properties of piracetam were observed in clinical trials. In the meantime, hundreds of drugs have been evaluated in clinical trials or in preclinical experiments. To classify the compounds, a concept is proposed assigning drugs to 19 categories according to their mechanism(s) of action, in particular drugs interacting with receptors, enzymes, ion channels, nerve growth factors, re-uptake transporters, antioxidants, metal chelators, and disease modifying drugs, meaning small molecules, vaccines, and monoclonal antibodies interacting with amyloid-β and tau. For drugs, whose mechanism of action is not known, they are either classified according to structure, e.g., peptides, or their origin, e.g., natural products. The review covers the evolution of research in this field over the last 25 years.
    Journal of Alzheimer's disease: JAD 11/2012; 34(1). DOI:10.3233/JAD-121729 · 4.15 Impact Factor
Show more